The Current Status of Lamivudine-Treated Patients with Chronic Hepatitis B

SUN Mi-shu,WANG Gui-qiang,ZHANG Wei,LI Jie,ZHUANG Hui
DOI: https://doi.org/10.16506/j.1009-6639.2012.01.015
2012-01-01
Abstract:Objective To investigate the current status of lamivudine(LAM)-treated patients with chronic hepatitis B(CHB) in China,and to provide the basic data for further optimizing the treatment of CHB patients.MethodsA questionnaire survey was conducted in this study.A total of 684 hepatologists from 741 hospitals selected from 110 cities of China,and the CHB patients treated by LAM were enrolled in this study.ResultsAccording to data provided by 684 hepatologists,39.58%(271/684) of patients were treated by LAM,and 65.50%(448/684) of them could pay 500 to 1,000 yuan per month for the cost of antiviral therapy.Among HBeAg-positive patients treated with LAM,the proportions of treatment withdrawals by patients themselves,with poor efficacy and meeting the endpoint of therapy were 46.74%(1120/2396),23.04%(552/2396) and 30.22%(724/2396),respectively.Among the HBeAg-negtive group,the figures were 48.95%(512/1046),22.47%(235/1046) and 28.59%(299/1046),respectively.There was no significant difference between the two groups(P0.05).Among the 1632 CHB patients with patients self-withdrawal, the gross cumulative discontinuation rates of antiviral therapy at 1,2,3 years were 24.26%,58.26% and 80.58%,respectively.The figures for the 787 cases with withdrawal of poor efficacy were 18.93%,55.14%, 78.53%,respectively.Of the 1023 CHB patients with withdrawal of meeting the endpoint of treatment,46.53% had treated for 2-3 years,and 53.47% for over 3 years.The reasons for LAM treatment withdrawal within 1 year of the CHB patients were self-withdrawal in 72.66%(396/545),poor efficacy in 27.34%(149/545) and meeting the endpoint of treatment in 0.The figures were 68.84%(959/1393),31.16%(434/1393) and 0 for the patients of withdrawal within 2 years;54.59%,25.65%(618/2409) and 23.23%(476/2409) for those of withdrawal within 3 years;30.69%(317/1033),16.36%(169/1033) and 52.95%(547/1033) for those of withdrawal over 3 years.ConclusionsA significant proportion of CHB patients are treated with LAM in China at present.Their economic affordability and treatment compliance are poor.Therefore,it is important to optimize the LAM therapy strategy and to improve the treatment compliance of CHB patients.
What problem does this paper attempt to address?